We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

66 hedge funds and large institutions have $132M invested in Enanta Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

51% more capital invested

Capital invested by funds: $87.3M → $132M (+$44.4M)

22% more funds holding

Funds holding: 54 → 66 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

41% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 22

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
13
Reduced
22
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$31.5M
2
CCM
Consonance Capital Management
New York
+$6.83M
3
Millennium Management
Millennium Management
New York
+$2.61M
4
SM
Sabby Management
Florida
+$2.08M
5
EI
EAM Investors
California
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
AP
AlpInvest Partners
Netherlands
-$9.18M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$7.43M
3
Franklin Resources
Franklin Resources
California
-$5.62M
4
SONJCPFA
State of New Jersey Common Pension Fund A
New Jersey
-$2.58M
5
SCM
Sigma Capital Management
Connecticut
-$1.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$35.4M +$31.5M +1,298,476 New
CCM
2
Consonance Capital Management
New York
$23.2M +$6.83M +281,801 +49%
Franklin Resources
3
Franklin Resources
California
$8.16M -$5.62M -231,700 -44%
WSA
4
Wall Street Associates
California
$7.38M +$376K +15,500 +6%
AP
5
AlpInvest Partners
Netherlands
$4.49M -$9.18M -378,901 -70%
SAM
6
Senzar Asset Management
New York
$4.38M +$3.89M +160,471 New
Barclays
7
Barclays
United Kingdom
$4.13M -$1.31M -54,234 -26%
BBA
8
Baker Bros. Advisors
New York
$2.98M -$385K -15,903 -13%
Millennium Management
9
Millennium Management
New York
$2.93M +$2.61M +107,519 New
BFA
10
BlackRock Fund Advisors
California
$2.72M -$108K -4,448 -4%
TI
11
Turner Investments
Pennsylvania
$2.61M -$195K -8,030 -8%
B
12
Bailard
California
$2.48M -$960K -39,600 -30%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$2.39M +$490K +20,239 +30%
SM
14
Sabby Management
Florida
$2.35M +$2.08M +85,946 New
EI
15
EAM Investors
California
$1.85M +$1.64M +67,708 New
Renaissance Technologies
16
Renaissance Technologies
New York
$1.75M +$1.56M +64,300 New
GPCM
17
Granite Point Capital Management
Massachusetts
$1.64M +$1.45M +60,000 New
RFC
18
Russell Frank Company
Washington
$1.47M +$972K +40,126 +200,630%
Northern Trust
19
Northern Trust
Illinois
$1.46M +$96.4K +3,977 +8%
BIT
20
BlackRock Institutional Trust
California
$1.45M -$701K -28,935 -35%
MWNA
21
Marshall Wace North America
New York
$1.37M +$1.21M +50,097 New
Two Sigma Investments
22
Two Sigma Investments
New York
$1.34M +$1.19M +49,148 New
Vanguard Group
23
Vanguard Group
Pennsylvania
$1.34M +$448K +18,489 +60%
State Street
24
State Street
Massachusetts
$1.17M +$208K +8,603 +25%
IHM
25
Iguana Healthcare Management
New York
$1.09M +$969K +40,000 New
1
2 3 4

ENTA Hedge Fund Activity: Q4 2013 in Review

66 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2013, worth a combined $132M — up 51% from $87.3M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ENTA positions and 15 closed out — a net gain of 12 holders — while 13 added to existing stakes and 22 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $31.5M. The largest seller was AlpInvest Partners, cutting an estimated $9.18M.

  • 66 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2013, up from 54 in Q3 2013.
  • Funds reported $132M of Enanta Pharmaceuticals stock for Q4 2013, up 51% quarter-over-quarter.
  • 27 funds opened new Enanta Pharmaceuticals positions in Q4 2013 and 15 closed out, a net change of +12 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $31.5M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2013 was AlpInvest Partners, an estimated $9.18M sold.

Based on aggregated 13F filings for Q4 2013.